Core Insights - Silexion Therapeutics Corp. has announced new preclinical results showing the synergistic efficacy of its siRNA candidate SIL-204 in combination with first-line chemotherapy agents for pancreatic cancer, specifically 5-fluorouracil and irinotecan, as well as gemcitabine [2][4] Group 1: Preclinical Results - SIL-204 demonstrates significant synergistic activity with 5-fluorouracil and irinotecan in human pancreatic tumor cell lines with KRAS G12D mutations, which are the most common mutations in pancreatic cancer [2][3] - The combination of SIL-204 with 5-fluorouracil and irinotecan resulted in a significant reduction in cancer cell confluence after approximately three days, with a p-value of less than 0.0005, indicating strong statistical significance [3] Group 2: Clinical Development Plans - Silexion plans to initiate toxicology studies for SIL-204 in the upcoming months and aims to advance it into Phase 2/3 clinical trials in the first half of 2026, focusing on locally advanced pancreatic cancer (LAPC) [5] - The company is also preparing to conduct preclinical studies for SIL-204 in colorectal cancer models [5] Group 3: Company Overview - Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference therapies targeting KRAS mutations, which are prevalent in various cancers [6] - The company's first-generation product, LODER™, has shown promising results in Phase 2 trials for non-resectable pancreatic cancer, indicating a strong foundation for its ongoing research and development efforts [6]
Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies